Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Bioceres Crop Solutions (BIOX) Receivables - Other (2017 - 2025)

Bioceres Crop Solutions' Receivables - Other history spans 9 years, with the latest figure at $22.6 million for Q2 2025.

  • On a quarterly basis, Receivables - Other rose 35.85% to $22.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $22.6 million, a 35.85% increase, with the full-year FY2025 number at $22.6 million, up 35.85% from a year prior.
  • Receivables - Other hit $22.6 million in Q2 2025 for Bioceres Crop Solutions, up from $16.6 million in the prior quarter.
  • Over the last five years, Receivables - Other for BIOX hit a ceiling of $28.8 million in Q2 2023 and a floor of $3.7 million in Q2 2022.
  • Historically, Receivables - Other has averaged $16.6 million across 5 years, with a median of $16.6 million in 2024.
  • Biggest five-year swings in Receivables - Other: tumbled 67.26% in 2022 and later surged 689.37% in 2023.
  • Tracing BIOX's Receivables - Other over 5 years: stood at $11.2 million in 2021, then tumbled by 67.26% to $3.7 million in 2022, then surged by 689.37% to $28.8 million in 2023, then crashed by 42.32% to $16.6 million in 2024, then surged by 35.85% to $22.6 million in 2025.
  • Business Quant data shows Receivables - Other for BIOX at $22.6 million in Q2 2025, $16.6 million in Q2 2024, and $28.8 million in Q2 2023.